SciVision Biotech Inc.

TWSE:1786 株式レポート

時価総額:NT$7.2b

SciVision Biotech バランスシートの健全性

財務の健全性 基準チェック /66

SciVision Biotechの総株主資本はNT$1.7B 、総負債はNT$206.1Mで、負債比率は12.1%となります。総資産と総負債はそれぞれNT$2.3BとNT$632.9Mです。 SciVision Biotechの EBIT はNT$232.4Mで、利息カバレッジ比率-19.8です。現金および短期投資はNT$861.3Mです。

主要情報

12.1%

負債資本比率

NT$206.13m

負債

インタレスト・カバレッジ・レシオ-19.8x
現金NT$861.28m
エクイティNT$1.70b
負債合計NT$632.94m
総資産NT$2.33b

財務の健全性に関する最新情報

Recent updates

Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?

Oct 11
Is Now The Time To Put SciVision Biotech (TWSE:1786) On Your Watchlist?

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Aug 30
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

Jul 22
SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's

SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

Jun 28
SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50

SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

Jun 14
SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings

SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Jun 04
SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly

Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Apr 01
Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Apr 20
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Apr 02
SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital

Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Mar 15
Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?

Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Feb 25
Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Feb 05
Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?

Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Jan 18
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly

Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

Jan 01
Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?

SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Dec 14
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years

Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

Nov 25
Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend

財務状況分析

短期負債: 1786の 短期資産 ( NT$1.2B ) が 短期負債 ( NT$362.3M ) を超えています。

長期負債: 1786の短期資産 ( NT$1.2B ) が 長期負債 ( NT$270.6M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: 1786総負債よりも多くの現金を保有しています。

負債の削減: 1786の負債対資本比率は、過去 5 年間で22.1%から12.1%に減少しました。

債務返済能力: 1786の負債は 営業キャッシュフロー によって 十分にカバー されています ( 145.3% )。

インタレストカバレッジ: 1786支払う利息よりも稼ぐ利息の方が多いので、利息支払い の補償は問題になりません。


貸借対照表


健全な企業の発掘